BioSpace News Archive

Seneca Therapeutics, Inc., announced that Dr. Paul Hallenbeck will present a talk at the 8th Oncolytic Virotherapy Summit 2023 entitled “Assessing the Benefits and Challenges of Intravenous Delivery of Oncolytic Viruses”.

Vapotherm, Inc., announced its intention to voluntarily delist its common stock from The New York Stock Exchange and its filing of an application to have its common stock quoted on the OTCQX Marketplace.

Merck & Co. and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157).

BioXcel Therapeutics, Inc. today announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates.

Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the National Academies of Sciences, Engineering, and Medicine Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures public meeting on Thursday December 14, 2023.

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today reported third quarter 2023 financial results and provided operational highlights.

Codexis, Inc. hosted a virtual Key Opinion Leader event on Friday, December 8, 2023, to discuss the growth of RNA interference therapeutics as a modality, the manufacturing landscape and the potential role for the Company’s Enzyme-Catalyzed Oligonucleotide Synthesis™ platform to enable commercial-scale production of RNAi therapeutics.

Axsome Therapeutics, Inc. today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD).

HanAll Biopharma’s partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson’s disease and other Nurr1-related human disorders, is pleased to announce the appointment of Dr. Almira Chabi, MD, EGMP to its Board of Directors, effective November 24, 2023.

STRM.BIO presented the first preclinical data on their novel delivery platform that uses megakaryocyte-derived EVs to target hematopoietic stem/progenitor cells (HSPCs) in the bone marrow at the American Society of Hematology (ASH) annual meeting being held in San Diego, California, December 9 – 12, 2023.